Sucampo, R-Tech Ueno and Takeda file patent infringement lawsuit against Anchen for AMITIZA

Sucampo Pharmaceuticals, Inc. ("Sucampo") announced that it, together with R-Tech Ueno, Ltd., Sucampo AG, and Takeda Pharmaceutical Company Limited ("Takeda") and certain affiliates of Takeda, has filed a patent infringement lawsuit against Anchen Pharmaceuticals, Inc. ("Anchen"), which had filed Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) to market a generic version of AMITIZA^® (lubiprostone) oral capsules, and certain affiliates of Anchen.

As a result of Sucampo's filing of the said lawsuit, final FDA approval of Anchen's ANDA will be stayed up to 30 months from January 2, 2013.